DB
IOVA icon

Dmitry Balyasny’s Iovance Biotherapeutics IOVA Stock Holding History

Dmitry Balyasny’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-300,000
Closed -$9.88M – 1514
2020
Q3 		$9.88M Buy
+300,000
New +$9.2M 0.07% 386

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Dmitry Balyasny's IOVA Position: Q2 2026 in Review

Dmitry Balyasny increased its Iovance Biotherapeutics (IOVA) stake by 50% in Q2 2026, buying an estimated $473K and bringing the position to 373,284 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1955.

Dmitry Balyasny first reported a position in IOVA in Q2 2018 and has held it in 28 quarters since. The position peaked at $42M in Q3 2024. 289 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Dmitry Balyasny held 373,284 shares of Iovance Biotherapeutics worth $1.55M as of Q2 2026.
  • Dmitry Balyasny bought 124,520 Iovance Biotherapeutics shares in Q2 2026, an estimated $473K.
  • Iovance Biotherapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1955 holding.
  • Dmitry Balyasny first reported a position in Iovance Biotherapeutics in Q2 2018 and has held it in 28 quarters since.
  • Dmitry Balyasny's Iovance Biotherapeutics position peaked at $42M in Q3 2024.
  • 289 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.